Member Articles

Update on Global Blood Therapeutics

by

As the calendar flips over, the new year has seemed to have reignited investors’ passion for the biotech sector. Bioverativ has been acquired, and we’re happy about that, but a timely update on the fortunes of Global Blood Therapeutics is now in order, too. By Alexander J. Poulos A look at the performance of the equity markets in general speaks to an investment community that is fine with taking on great risks. The performance of the iShares Nasdaq Biotechnology ETF (IBB) has also been stellar, rising more than 10% since the start of the new year. We can’t complain, and we hope that some of our risk-seeking readers we’re blown away with excitement when Sanofi (SNY) announced that it would … Read more

Dividend Increases/Decreases for the Week Ending January 26

by

Below we provide a list of firms that raised/lowered their dividends during the week ending January 26. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week 3M (MMM): now $1.36 per share quarterly dividend, was $1.17. AGCO (AGCO): now $0.15 per share quarterly dividend, was $0.14. Air Products and Chemicals (APD): now $1.10 per share quarterly dividend, was $0.95. Alaska Air (ALK): now $0.32 per share quarterly dividend, was $0.30. ALLETE (ALE): now $0.56 per share quarterly dividend, was $0.535. Alliance Data Systems (ADS): now $0.57 per share quarterly dividend, was $0.52. … Read more

Airlines to Start a Price War?

by

Some have said the airline industry has changed. We’ve always been cautious on the structural characteristics of the airline business, and United Continental has reminded us why. By Kris Rosemann and Brian Nelson, CFA The US Treasury is scheduled to announce its plans to finance the government’s shortfall over the next three months January 31, and many are forecasting a significant rise in the sale of government paper. 2018 could mark the first year the government will increase Treasury bond sales, and some estimates have the issuance at more than $1 trillion, the highest level since 2010. The current 10-year Treasury yield is ~2.65%, and a significant influx of supply into the Treasury bond market could drive prices meaningfully lower, … Read more

Bioverativ’s Takeout, Visa’s Surge, and General Electric’s Pain

by

From Bioverativ’s takeout to Visa’s stock price surge to General Electric’s continued pain, there’s a lot going on in the stock market. Let’s cover some ground. By Kris Rosemann and Brian Nelson, CFA It’s hard to believe this but our best idea in the Best Ideas Newsletter portfolio, Visa (V), is now a $124+ per share stock. We know how to pick ‘em, would you say? We don’t get everything correct, of course, but if you’ve read anything on our website, we can only hope that you’ve witnessed Visa’s meteoric rise. The high end of our updated fair value estimate range for Visa is north of $130 per share. What a wild ride it has been, to say the least, … Read more

Dropping Coverage of A Few Apparel Makers

by

Valuentum is dropping coverage of a few apparel makers to focus resources elsewhere. Structure of the Retail–Apparel Industry The retail clothing space is incredibly competitive, very fragmented, and heavily exposed to cyclical pressures and consumer spending patterns. Distribution and storefronts remain crucial, but online threats are becoming ever more apparent. Predicting the correct fashion styles during various seasons of the year continues to be the primary driver impacting the operating results of constituents, and brands can fall out of favor with consumers relatively quickly. Though some firms have developed a dedicated customer following that has helped mitigate abrupt market share shifts, we’re generally neutral on the industry. Ascena Retail (ASNA) Ascena Retail continues to face meaningful comparable sales declines, and … Read more

GlaxoSmithKline: Not All Dividends Are Created Equal

by

Many seeking ideas to generate dividend income may be drawn to slow-growing entities with large dividend yields. However, without proper examination of the balance sheet and competitive position, an investor may enter a position banking on a steady dividend stream only to be caught by a sudden cut in the dividend. It is growing increasingly likely that GlaxoSmithKline may be ready to sacrifice the dividend on the altar in the name of additional M&A, in our view. By Alexander J. Poulos GSK Overview GlaxoSmithKline (GSK) remains a venerable European entity with a number of business lines similar to its US rivals such as Pfizer (PFE). At GSK’s core is its heavy reliance on research to bring forth additional novel branded … Read more

Gilead Sciences’ HCV Guidance Is the Star of the Show

by

Shares of Gilead Science have been held hostage due to the vagaries of the HCV business. The shares blasted through $100 as the initial sales ramp for its suite of HCV meds took the market by storm. The record revenues posted in 2015 proved to be unsustainable, however, as the curative nature of the treatment meaningfully decreased the eligible pool of patients much to the benefit of society. The Street subsequently punished shares of Gilead as the equity made a near roundtrip back down the high $60’s. The investment community has maintained a near-maniacal obsession with the HCV pipeline with the latest fear of a new competitor stealing share. Let’s examine these key points a bit further. By Alexander J. … Read more

Hanesbrands Leaps, IBM Falters and More

by

We were pleased to see the recent performance of Hanesbrands, and we continue to think IBM is not yet out of the woods, despite some life with respect to revenue trends. Let’s cover this and more. By Kris Rosemann There are a lot of things happening in the markets these days. For starters, growth in the world’s second-largest economy accelerated for the first time in seven years as China’s reported growth of 6.9% in 2017 was slightly higher than the 6.7% it achieved in 2016 and the projected growth rate for 2017 of ~6.5%. However, many observers are anticipating a return to the slowing trends of years past as the Chinese government works to reduce risky lending in areas such … Read more

Brewing the Next Dividend Aristocrat

by

Image Source: Starbuck’s 2017 annual Shareholder Meeting Most income-minded investors would love to find the next Dividend Aristocrat before it earns such a title, but many continue to focus on the stars of the past instead of working to identify up and coming dividend track records, which often carry higher dividend growth rates than the most established Dividend Aristocrats. By Alexander J. Poulos McDonald’s Is Pretty Good… Starbucks (SBUX) has a number of qualities that we look for in identifying companies that can sustain a growing dividend over time, one that has the potential to develop into a Dividend Aristocrat. The company’s dividend track record is still a young one as the payout was initiated in 2010, but forward-looking analysis … Read more

In the News: GE, O, EGO, CELG

by

There is a lot happening in the markets. Let’s have a look at some of the top news. By Kris Rosemann On January 16, General Electric (GE) announced a $6.2 billion write down related to its legacy reinsurance business, and market observers have taken to speculating about the fate of the industrial giant. Activist investor Nelson Peltz’s Trian Fund Management, which has watched the market value of its 2015 investment in GE dwindle, is reportedly pushing the conglomerate to explore strategic alternatives. Peltz and Trian have been in the middle of a number of battles for strategic power at the top of a number of US-based behemoths including the recently formed DowDuPont (DWDP) and Procter & Gamble (PG), and Trian … Read more